Spots Global Cancer Trial Database for Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Official Title: An Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)

Study ID: NCT06387056

Conditions

Locally Advanced Prostate Cancer

Oligometastatic Prostate Cancer

Interventions

Rezvilutamide

Goserelin Microspheres for Injection

Study Description

Brief Summary: To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

Detailed Description: According to the results of the genomic profile, patients will be assigned to 4 neoadjuvant therapy (NT) groups (Queue 1 to 4): Queue 1: No targetable actionable aberration; Queue 2: Homologous recombination repair (HRR) alterations (BRCA1/2); Queue 3: Homologous recombination repair alterations (except BRCA1/2 and CDK12); Queue 4: MSI-H/dMMR, TMB≥10mut/Mb or CDK12 alterations without other HRR alterations. A following PSMA PETCT for evaluating the efficacy of NT and radical prostatectomy (RP) plus pelvic lymph node dissection (PLND) will be perform. The histopathological and survival data after RP plus PLND will also be evaluated.